Amgen says Lumakras cuts risk of lung cancer progression by 34%
By Deena Beasley (Reuters) – Amgen Inc’s Lumakras pill reduced the risk of disease progression in patients with advanced lung cancer by 34% compared with chemotherapy in a clinical trial,…